Pasithea Therapeutics Corp（KTTA）财务数据KTTAPasithea Therapeutics Corp

Evaluating the bottom line, Pasithea Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -65.49%, provide a clear picture of how effectively KTTA converts its operational activities into shareholder value.

In the context of the broader market, KTTA competes directly with industry leaders such as RKTO and PBM. With a market capitalization of $19.23M, it holds a leading position in the sector. When comparing efficiency, KTTA's gross margin of N/A stands against RKTO's N/A and PBM's N/A. Such benchmarking helps identify whether Pasithea Therapeutics Corp is trading at a premium or discount relative to its financial performance.

Pasithea has shown a troubling financial performance with consistent net losses, including a net income loss of $10,110,868 in Q4 2025 and a gross profit of $0 in Q4 2024. The company has a negative P/E ratio of -0.001517, indicating that it is not generating profits.